Osteoporosis is a disease characterized by low bone mass and structural deterioration of bone tissue, which leads to greater fragility and an increase in fracture risk. Osteoporosis is also a silent disease, often displaying no signs or symptoms until a fracture occurs, leaving the majority of patients undiagnosed and untreated, representing a high unmet medical need. Osteoporosis is a progressive bone disease that is characterized by a decrease in bone mass and density. It occurs when the total bone lose exceeds the total bone formation. As a result, the bones become weak and have an increased chance of breaking or fracturing. The debilitating effects of osteoporosis have substantial costs and osteoporotic fractures create a significant healthcare burden.
There are two categories of osteoporosis medications: antiresorptive medications that slow bone loss and anabolic drugs that increase the rate of bone formation.
Antiresorptive medications include bisphosphonates which interfere with bone resorption while PTH is an anabolic (bone forming) drug.
Although PTH (teriparatide) would be the drug of choice for this disease, the high cost, low dosing flexibility and inconvenience of a daily injection, make it less desirable for patients. Entera’s platform technology has taken PTH and enabled it to be delivered orally which should lead to higher compliance rates. Additionally, physicians would potentially prescribe the oral PTH 1-34 to a wider population of osteoporosis patients and at an earlier stage of the disease.